About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

AstraZeneca India: The National Drug Pricing Authority of India has issued an 8 million rupee demand notice for alleged overcharging.

2026-07-28

AstraZeneca India: The National Drug Pricing Authority of India has issued an 8 million rupee demand notice for alleged overcharging.

Other News
2026-07-28

The U.S. Senate advanced Walter Clayton's nomination as Director of National Intelligence by a vote of 51 to 43.

The U.S. Senate advanced Walter Clayton's nomination as Director of National Intelligence by a vote of 51 to 43.
2026-07-28

[Interbank Foreign Exchange Market Central Parity Rate for the Renminbi on July 28, 2026] USD/CNY was quoted at 6.7928, up 17 points (CNY depreciation); EUR/CNY was quoted at 7.7119, down 148 points; HKD/CNY was quoted at 0.86627, up 2.6 points; GB

[Interbank Foreign Exchange Market Central Parity Rate for the Renminbi on July 28, 2026] USD/CNY was quoted at 6.7928, up 17 points (CNY depreciation); EUR/CNY was quoted at 7.7119, down 148 points; HKD/CNY was quoted at 0.86627, up 2.6 points; GBP/CNY was quoted at 9.0141, down 353 points; AUD/CNY was quoted at 4.7380, down 20 points; CAD/CNY was quoted at 4.8012, down 101 points; 100 JPY/CNY was quoted at 4.1427, down 14 points; CNY/RUB was quoted at 11.5215, up 389 points; NZD/CNY was quoted at 3.9140, down 148 points; CNY/MYR was quoted at 0.60204, down 0.7 points; CHF/CNY was quoted at 8.2825, down 231 points; The Singapore dollar/Chinese yuan exchange rate was 5.2514, down 56 points.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.